According to the Graphical Research new growth forecast report titled North America Bioreactors Market value is set to exceed USD 4.5 billion by 2026. Rising demand for vaccines and other biologics drugs has escalated the use of bioreactors in manufacturing and research units. With rising demand for personalized biopharmaceuticals, new players have entered the market. Thus, growing number of pharmaceutical and biotechnology companies has expanded the use of bioreactors in the region. Moreover, collaborations of major market players with government has further fostered the bioreactors market growth.
The outbreak of COVID-19 has affected millions of people in North America region. More than six million people are affected by this pandemic till date and the region accounts for the maximum number of deaths in the world. Hence, rapidly increasing number of COVID-19 cases has driven the demand for vaccines to reduce the mortality rate, thereby increasing the growth potential for bioreactors in the region.
However, concerns about leachables & extractables for single-use bioreactors and stringent government regulations may impede the market growth during the analysis period.
Single-use segment held substantial revenue share in 2019 and is anticipated to witness 17.9% CAGR during the forecast time period. Owing to various advantages over other bioreactors, single-use technology is being widely used in the pharmaceutical industry. Factors such as cost-efficiency, increased productivity, easy disposal of the residues, and reduced cross-contamination will favor the use of single-use bioreactors, thus driving the segment growth.
Bacterial cells segment was valued over USD 280 million in 2019. Use of bacterial cells for cultivation in bioreactors has had a positive effect on the pharmaceutical and biotechnology industry. Due to capacity to offer large number of industrial applications and ability to create cell lines for human therapeutic use, bacterial cells are widely used in the healthcare industry. Moreover, these cells are robust, resistant to shear damage and can endure high agitation rate. Thus, aforementioned factors will foster bacterial cell segment in the future.
Vaccines segment held a significant share in 2019 and was valued at over USD 670 million. Increasing incidence of chronic disorders and infectious diseases in North America coupled with rising healthcare expenditure by the government will drive the segment growth. According to the Centers for Disease Control and Prevention (CDC), around 15 million people in the U.S. visit physician’s offices with parasitic and infectious diseases. Additionally, 4 million people visit emergency departments and are diagnosed with infectious disease. Therefore, with growing cases of infectious diseases, vaccines segment will witness lucrative growth in the region during analysis period.
Biopharma manufacturers held over 47% revenue share in 2019 and it is anticipated follow a similar trend over the forecast period. Rising need for large number of therapeutics, orphan drugs and other personalized medicines will be the major growth driving factors for adoption of bioreactors by biopharma manufacturers. Production of metabolites and increasing downstream operations will further spur the adoption rate of bioreactors among biopharma manufacturers, thus boosting the segment growth in the region.
Canada bioreactors market is estimated to witness 15.7% CAGR during forecast period. Due to rising number of COVID-19 cases and high mortality rate in the country, there is a rapid increase in the demand for the vaccine development. Moreover, rising healthcare expenditure by the government and expanding healthcare facilities will foster the bioreactors market growth in the country.
Major market players in market are Eppendorf AG, Cytiva, Sartorius Stedim Biotech, Merck Group, and Thermo Fischer among others. These market players are undertaking various organic strategies such as product innovation, mergers and acquisitions to expand their business in the region.
North America bioreactor market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2015 to 2026, for the following segments:
Market Share, By Product Type, 2015-2026 (USD Million)
Market Size, By Cell, 2015 – 2026 (USD Million)
- Mammalian Cells
- Bacterial Cells
- Yeast Cells
Market Growth, By Molecule, 2015 – 2026 (USD Million)
- Monoclonal Antibodies
- Recombinant Proteins
- Stem Cells
- Gene Therapy
Market Value, By End-use, 2015-2026 (USD Million)
- R&D Organizations
- Biopharma Manufacturers
The above information is provided for the following region and countries: